Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Features
AMS Features
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis
By
- AMS
posted
Apr 01, 2020 01:00 PM
0
Recommend
Volume 32, Issue 7
, November 2021, Page 693-700
.
0 comments
0 views
Permalink
Related Content
Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry
- AMS
Added Feb 28, 2020
Blog Entry
Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries
- AMS
Added Mar 06, 2020
Blog Entry
Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States
- AMS
Added Jun 30, 2020
Blog Entry
Efficacy and safety of artemether emulsion for the treatment of mild-to-moderate acne vulgaris: a randomized pilot study
- AMS
Added Jan 09, 2020
Blog Entry
Randomized, controlled trial testing the effectiveness and safety of 2.5% and 5% benzoyl peroxide for the treatment of pitted keratolysis
- AMS
Added Jan 04, 2020
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic